Avelumab and Merkel Cell Carcinoma: Examining the Evidence on Risk

From General Health to Targeted Safety Inquiry

This domain has historically provided accessible health and science information, covering broad wellness topics and disease prevention for the general public. That foundation established a baseline of non-specialized knowledge about maintaining health and understanding common medical conditions. The current content pivots toward a more focused occupational exposure concern, specifically examining the relationship between Avelumab administration and Merkel Cell Carcinoma risk. This shift moves from general health education to a targeted inquiry into pharmaceutical safety within clinical and manufacturing environments. The bridge concept connects the prior general health context to the specific question of whether Avelumab exposure, particularly in occupational settings such as drug production or administration, may influence Merkel Cell Carcinoma risk. This pivot reframes the discussion from passive health information consumption to active risk assessment for workers and healthcare professionals who handle this therapeutic agent. The transition maintains a neutral academic tone, avoiding mechanistic claims while establishing the relevance of studying exposure-outcome associations in controlled environments. The focus remains on what studies show regarding the potential link, without venturing into disease-specific mechanisms or citing external evidence.

Understanding Avelumab and Its Role in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) and functions as an immune checkpoint inhibitor (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). Approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is thus the first therapeutic agent specifically approved for use in this indication, and is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is a rare, highly aggressive skin cancer with neuroendocrine differentiation (https://pubmed.ncbi.nlm.nih.gov/36450381/). Approximately 80% of cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385/). The incidence rate of MCC is increasing, and MCC is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors (ICIs) offer durable responses and significant clinical benefit, with two agents—avelumab (anti-PD-L1) and pembrolizumab (anti-PD-1)—currently approved by the U.S. Food and Drug Administration for the treatment of advanced MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/). Despite these advances, approximately 50% of patients with advanced MCC treated with ICI progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Furthermore, 50% of patients do not respond or develop ICI-induced, immune-related adverse events (irAEs), due to diverse mechanisms such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/).

Therapeutic vs. Causative Relationship: What the Evidence Shows

The mechanistic pathways linking avelumab to Merkel cell carcinoma are primarily therapeutic rather than causative. Avelumab is used to treat MCC, not to cause it. However, the risk narrative must address the possibility that avelumab could be associated with adverse outcomes in some patients. The evidence indicates that avelumab-refractory MCC is a recognized clinical scenario. For avelumab-refractory patients, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). In a retrospective study at three different sites in Germany, clinical and molecular data of patients with metastatic MCC being refractory to the PD-L1 inhibitor avelumab and who were later treated with combined ipilimumab/nivolumab were collected and evaluated. Three out of five patients responded to combined IPI/NIVO according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG similarly reported that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, for avelumab-refractory patients, alternative treatments such as ipilimumab plus nivolumab may be considered (https://pubmed.ncbi.nlm.nih.gov/35877101/). Regarding causation-related considerations for affected patients, the timeline between exposure and documented harm is relevant. Avelumab is administered as a therapeutic agent for MCC, so exposure occurs after diagnosis. The harm in question is not the development of MCC but rather progression or lack of response to avelumab therapy. The evidence shows that approximately 50% of patients with advanced MCC treated with ICI progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). This progression can occur during or after treatment, and the timeline varies among patients. Immune-related adverse events can also occur, potentially leading to treatment discontinuation or additional morbidity. The adequacy of warnings regarding avelumab and Merkel cell carcinoma is addressed in the prescribing information, which includes warnings about immune-mediated adverse reactions. However, the evidence snippets do not provide specific details on the content of those warnings. The risk for patients is that avelumab may not be effective, or may be associated with adverse events, but the evidence does not suggest that avelumab causes MCC. In summary, avelumab is an established treatment for metastatic MCC, with a demonstrated response rate in approximately one-third of chemotherapy-refractory patients. However, about half of patients do not respond or experience progression, and immune-related adverse events are a known risk. For patients who are refractory to avelumab, alternative immunotherapies such as ipilimumab plus nivolumab may offer benefit. The evidence does not support a causal link between avelumab and the development of MCC; rather, avelumab is used to treat the disease. Clinicians should monitor patients for progression and adverse events, and consider alternative treatments when appropriate.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, the evidence does not support a causal link between avelumab and the development of Merkel cell carcinoma. Avelumab is a therapeutic agent used to treat metastatic MCC, not to cause it. The risk for patients is that avelumab may not be effective or may be associated with adverse events, but it does not cause the disease.

What is the risk of progression for patients treated with avelumab?

Approximately 50% of patients with advanced Merkel cell carcinoma treated with immune checkpoint inhibitors like avelumab progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). This progression can occur during or after treatment, and the timeline varies among patients.

Are there alternative treatments for patients who do not respond to avelumab?

Yes, for avelumab-refractory patients, alternative immunotherapies such as ipilimumab plus nivolumab may be considered. A retrospective study reported that three out of five patients responded to combined ipilimumab/nivolumab (https://pubmed.ncbi.nlm.nih.gov/33439294/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.